Bergna C, Marin G H, Maiz M, Bruzzoni Giovanelli H, Ponzinibbio C, Schinella G, Errecalde J, Rebollo A
Faculty of Medical Science, National University of La Plata, Argentina.
Ceylon Med J. 2019 Jun 30;64(2):46-51. doi: 10.4038/cmj.v64i2.8890.
RAS-RAF-MEK-ERK is a key pathway for apoptosis regulation in cancer cells. B-Raf-inhibitors such as PLX4032 peptide was developed by Institute Curie-Université Pierre et Marie Curie in order to induce apoptosis in cancer cells.
To demonstrate pro-apoptotic properties and survival outcome of EP2014/064243 peptide in murine aggressive lymphoma.
BALBc mice with T-lymphoma were randomized assigned either in Group A (peptide+cyclophosphamide-CFM); Group B (peptides), Group C (CFM-control) or Control D (Cl-Na 0.9%-SF control group). Survival probability was calculated by Kaplan-Meier analysis. Apoptosis was detected using TUNEL technique. The protocol was approved by the Institutional Committee for Animal Care (CICUAL: T04-01-2015)
The median survival was 24 days (21.6-26.4) for placebo, 33 days (28.0-35.4) for the CFM monotherapy group, 33 (27.1-35.8) for the peptide group and 34 days (24,4-40) for CFM-peptide combined treatment (p<0.05). In lymph node tissue the mean TUNEL positive cells per field for each treatment group was 2, 12 and 13 and 35 for SF, CFM, peptide and combined therapy (p<0.05).
These findings suggest that in murine aggressive lymphoma treated by an experimental peptide in addition with CFM, had an exponentially pro-apoptotic effect than CFM alone, suggesting that the peptide potentiated the anti-tumoural effect of CFM.
RAS-RAF-MEK-ERK是癌细胞凋亡调控的关键通路。居里研究所-皮埃尔和玛丽·居里大学研发了诸如PLX4032肽等B-Raf抑制剂，以诱导癌细胞凋亡。
证明EP2014/064243肽在小鼠侵袭性淋巴瘤中的促凋亡特性和生存结果。
将患有T淋巴瘤的BALBc小鼠随机分为A组（肽+环磷酰胺-CFM）；B组（肽），C组（CFM-对照组）或D组（0.9%氯化钠溶液-生理盐水对照组）。通过Kaplan-Meier分析计算生存概率。使用TUNEL技术检测细胞凋亡。该方案已获得动物护理机构委员会（CICUAL：T04-01-2015）的批准。
安慰剂组的中位生存期为24天（21.6-26.4），CFM单药治疗组为33天（28.0-35.4），肽组为33天（27.1-35.8），CFM-肽联合治疗组为34天（24.4-40）（p<0.05）。在淋巴结组织中，每个治疗组每视野TUNEL阳性细胞的平均数，生理盐水组、CFM组、肽组和联合治疗组分别为2、12、13和35（p<0.05）。
这些发现表明，在小鼠侵袭性淋巴瘤中，实验性肽联合CFM治疗比单独使用CFM具有更强的促凋亡作用，提示该肽增强了CFM的抗肿瘤作用。
